PL3436019T3 - (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania

Info

Publication number
PL3436019T3
PL3436019T3 PL17776743T PL17776743T PL3436019T3 PL 3436019 T3 PL3436019 T3 PL 3436019T3 PL 17776743 T PL17776743 T PL 17776743T PL 17776743 T PL17776743 T PL 17776743T PL 3436019 T3 PL3436019 T3 PL 3436019T3
Authority
PL
Poland
Prior art keywords
amino
fluorotetrahydro
purin
trichlorophenyl
methylcyclohexane
Prior art date
Application number
PL17776743T
Other languages
English (en)
Inventor
Zheng Chen
Paul F. Fernandez
Tracy L. Gaebele
Lianfeng Huang
Matthew J. Jackson
Matthew M. Kreilein
Xiaoling Lu
Wenju Wu
Jean Xu
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of PL3436019T3 publication Critical patent/PL3436019T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17776743T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania PL3436019T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01
EP17776743.1A EP3436019B1 (en) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
PCT/US2017/025289 WO2017173218A1 (en) 2016-04-01 2017-03-31 Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Publications (1)

Publication Number Publication Date
PL3436019T3 true PL3436019T3 (pl) 2022-01-10

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17776743T PL3436019T3 (pl) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania

Country Status (19)

Country Link
US (2) US10047090B2 (pl)
EP (2) EP3845536A1 (pl)
JP (1) JP6995058B2 (pl)
CN (1) CN109819649B (pl)
AU (1) AU2017240050B2 (pl)
CA (1) CA3019105A1 (pl)
CY (1) CY1124677T1 (pl)
DK (1) DK3436019T3 (pl)
ES (1) ES2895419T3 (pl)
HR (1) HRP20211546T1 (pl)
HU (1) HUE056631T2 (pl)
LT (1) LT3436019T (pl)
MX (1) MX379439B (pl)
PL (1) PL3436019T3 (pl)
PT (1) PT3436019T (pl)
RS (1) RS62496B1 (pl)
SI (1) SI3436019T1 (pl)
SM (1) SMT202100604T1 (pl)
WO (1) WO2017173218A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230035424A (ko) 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
SG11201808388QA (en) * 2016-04-01 2018-10-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
ES3032365T3 (en) * 2016-06-21 2025-07-17 Assia Chem Ind Ltd Solid state forms of ixazomib citrate
EP3691687A1 (en) 2017-10-04 2020-08-12 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sólido
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN116710475A (zh) * 2020-12-15 2023-09-05 国家科学研究中心 Sqstm1及其在癌症疗法中的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CN101360725B (zh) 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
DK2279731T3 (da) 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
KR20230035424A (ko) * 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
SG11201808388QA (en) 2016-04-01 2018-10-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CA3019105A1 (en) 2017-10-05
US10513519B2 (en) 2019-12-24
SMT202100604T1 (it) 2021-11-12
WO2017173218A1 (en) 2017-10-05
PT3436019T (pt) 2021-11-04
ES2895419T3 (es) 2022-02-21
SI3436019T1 (sl) 2021-12-31
US20180362529A1 (en) 2018-12-20
MX379439B (es) 2025-03-10
CY1124677T1 (el) 2022-07-22
MX2018011970A (es) 2019-05-20
RS62496B1 (sr) 2021-11-30
DK3436019T3 (da) 2021-10-11
EP3436019A4 (en) 2019-08-28
EP3845536A1 (en) 2021-07-07
EP3436019B1 (en) 2021-07-28
CN109819649A (zh) 2019-05-28
JP2019515889A (ja) 2019-06-13
AU2017240050A1 (en) 2018-10-11
US10047090B2 (en) 2018-08-14
US20170283418A1 (en) 2017-10-05
LT3436019T (lt) 2021-10-25
EP3436019A1 (en) 2019-02-06
JP6995058B2 (ja) 2022-02-21
HRP20211546T1 (hr) 2022-01-07
AU2017240050B2 (en) 2021-12-16
CN109819649B (zh) 2023-02-28
HUE056631T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
SI3436019T1 (sl) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe
IL283531A (en) Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
IL285820A (en) Bicyclic heterocyclyl compounds and their uses
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
EP3558587A4 (en) ABRASIVE ARTICLE AND ITS MANUFACTURING PROCESS
EP3519137A4 (en) ABRASIVE ARTICLES AND METHOD FOR THE PRODUCTION THEREOF
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
IL281089A (en) LINGO–1 antagonists and uses for the treatment of demyelinating disorders
EP3512517B8 (en) Use of pridopidine for the treatment of anxiety and depression
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
PT3724196T (pt) Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
EP3466952A4 (en) NEW INHIBITOR OF FLT3 KINASE AND USES THEREOF
EP3651606A4 (en) PRECIOUS STONE COATINGS AND RELATED MANUFACTURING AND USE PROCEDURES
EP3248979A4 (en) Novel inhibitor of flt3 kinase and use thereof
EP3528928A4 (en) FILTER ARTICLES AND METHOD OF MANUFACTURING AND USE THEREOF
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
GB201720221D0 (en) Automotive components comprising ceramics novel inlays and methods of forming same
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
SI3408264T1 (sl) Nilotinibijev dinitrat (V) in njegove kristalne oblike
EP3504191A4 (en) HYDROFLUOROETHERS HAVING NITROGEN AND DIOXOLANE AND METHOD FOR USE THEREOF
IL273658A (en) Compounds and methods for using cis-4-[2-{[(3s,4r)-3-fluoroxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]- 1-Methylcyclohexane-1-carboxamide
HK40034727A (en) Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
IL254205B (en) Reagents for the acylation of amino acids and methods for their use
HK40030377A (en) Gemstone coatings and methods of making and using the same